Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Bendamustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 7/20 | 0.98 |
| ▸ | HDAC1 known ✓ | Q13547 | 4/20 | 0.98 |
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.98 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.98 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.98 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.98 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 2/20 | 0.98 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.98 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.98 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.51 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bendamustine SCHEMBL29352819 | 1.00 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL118499 | 0.99 | HDAC6 (0.96) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL9950832 | 0.99 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL26319 | 0.99 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29394147 | 0.99 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL12497247 | 0.98 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL15523734 | 0.98 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL15436003 | 0.97 | HDAC6 (0.96) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL2783279 | 0.96 | HDAC6 (0.90) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16772708 | 0.96 | HDAC6 (0.94) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6770 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4360621-B1 | FORMULATIONS OF BENDAMUSTINE | EAGLE PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4674432-A1 | COMBINATION DRUG CONTAINING CD20/CD47 BLOCKING BIFUNCTIONAL FUSION PROTEIN, AND USE THEREOF | Shanghai JMT-Bio Technology Co., Ltd. (CN) | 2026-01-07 | — | — | EP | claimed |
| US-20260000769-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-01-01 | — | — | US | claimed |
| WO-2010042568-A1 | PROCESSES FOR THE PREPARATION OF BENDAMUSTINE | CEPHALON, INC. (US) | 2010-04-15 | — | — | WO | claimed |
| CN-101691359-A | Method for synthesizing highly-pure bendamustine hydrochloride | SHENZHEN MAIN LUCK PHARMACEUTI | 2010-04-07 | — | — | CN | claimed |
| CN-101606934-A | Bendamustine hydrochloride composition | JIANGSU AOSAIKANG PHARMACEUTIC (CN) | 2009-12-23 | — | — | CN | claimed |
| CN-101584668-A | Bendamustine hydrochloride freeze-dried powder injection | JIANGSU AOSAIKANG PHARMACEUTIC (CN) | 2009-11-25 | — | — | CN | claimed |
| US-20090264488-A1 | NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE | CEPHALON, INC. (US) | 2009-10-22 | — | — | US | claimed |
| WO-2009120386-A2 | NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE | CEPHALON, INC. (US) | 2009-10-01 | — | — | WO | claimed |
| CN-101119708-A | Bendamustine lyophilized pharmaceutical compositions | CEPHALON INC (US) | 2008-02-06 | — | — | CN | claimed |
| EP-1863452-A2 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION | CEPHALON, INC. (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006076620-A2 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION | CEPHALON, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-20060159713-A1 | Bendamustine pharmaceutical compositions | CEPHALON, INC. (US) | 2006-07-20 | — | — | US | claimed |